Jakub Kucharz

Associate Professor

Centrum Onkologii-Instytut im Marii Skłodowskiej-Curie Warszawa

Poland

Research Interests

Explore related searches

Professors in Poland Professors in Immunology Immunology professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jakub Kucharz is an Associate Professor at Centrum Onkologii-Instytut im Marii Skłodowskiej-Curie in Warszawa, Poland. His research areas include metastatic renal cell carcinoma and urothelial carcinoma, with a focus on immune-based therapies and real-world treatment outcomes. Recent publications highlight his work on therapeutic comparisons and the impact of concomitant medications in cancer treatment.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Collaborators (6)

Radim Kubeš

University Hospital in Motol

CZECH REPUBLIC

View details

GRZEGORZ KAMINSKI

Head of the Department/Professor

Military Institute of Medicine National Research Institute

POLAND

View details

Sebastiano Buti

ITALY

View details

Ondrej Fiala

Charles University

CZECH REPUBLIC

View details

Marco Stellato

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Katarzyna Agnieszka Gniadek-Olejniczak

Deputy Head of Deparment

Wojskowy Instytut Medyczny

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jakub Kucharz

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study.

Theranostics in Renal Cell Carcinoma—A Step Towards New Opportunities or a Dead End—A Systematic Review

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2(EV) Study

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.

Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).

Low-grade myofibrosarcoma of the maxillary sinus: Two case reports.

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).

Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.

Mixed epithelial and stromal tumor of the kidney: A case report.

The quality of life in patients with at least moderate ischemic mitral regurgitation qualified to cardiosurgery treatment.

What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention.

Collaborators (6)

Radim Kubeš

GRZEGORZ KAMINSKI

Sebastiano Buti

Ondrej Fiala

Marco Stellato

Katarzyna Agnieszka Gniadek-Olejniczak

Make your next move.